Adicet Bio Inc

NASDAQ ACET

Data sourced from

and

Download Data

Adicet Bio Inc Payables Turnover 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending March 31, 2024: 483.93%

Adicet Bio Inc Payables Turnover 1 year YoY Change (%) is 483.93% for the Trailing 12 Months (TTM) ending March 31, 2024, a 583.22% change year over year. Payables turnover measures the efficiency with which a company manages its accounts payable. It is calculated by dividing the cost of revenue by the accounts payable. This ratio indicates how quickly a company pays off its obligations to suppliers and vendors. A higher turnover suggests that the company is efficiently managing its accounts payable, while a lower ratio may indicate a slower payment process or potential liquidity issues. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Adicet Bio Inc Payables Turnover for the Trailing 12 Months (TTM) ending March 31, 2022 was -0.17.
Adicet Bio Inc Payables Turnover for the Trailing 12 Months (TTM) ending March 31, 2020 was 114.84, a 13,763.02% change year over year.

NASDAQ: ACET

Adicet Bio Inc

CEO	Mr. Chen Schor BA, CPA, CPA, M.B.A., MBA
IPO Date	Jan. 26, 2018
Location	United States
Headquarters	200 Clarendon Street, Boston, MA, United States, 02116
Employees	143
Sector	Healthcare
Industry	Biotechnology

Description

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

Key trends